{"entity":{"id":"nct02506959","kind":"trial","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Busulfan, Gemcitabine, Melphalan and Panobinostat in Plasma cell leukaemia, run by M.D. Anderson Cancer Center, completed.","summary":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma is a phase 2 interventional study registered as NCT02506959 by M.D. Anderson Cancer Center, with 83 participants recorded, started 2015-09-14 and reaching its primary completion in 2024-06-03. Interventions recorded: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study. Conditions recorded: Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma.\n\nLinked to the drug Panobinostat because the registry names it among its interventions and Plasma cell leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02506959","url":"https://clinicaltrials.gov/study/NCT02506959"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["plasma-cell-leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["busulfan","gemcitabine","melphalan","panobinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02506959","phase":"2","setting":"Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma","sponsor":"M.D. Anderson Cancer Center","started":"2015-09-14","startedType":"actual","yearReported":2025,"enrolled":83,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression Free Survival (PFS)","primary":true,"unit":"participants","arms":[{"name":"Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel","n":50,"value":38,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-03-18), not from a publication"},{"name":"Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel","n":33,"value":24}],"source":"https://clinicaltrials.gov/study/NCT02506959?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"participants","arms":[{"name":"Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel","n":50,"value":27,"note":"Figures from the ClinicalTrials.gov results section (first posted 2025-03-18), not from a publication"},{"name":"Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel","n":33,"value":16}],"source":"https://clinicaltrials.gov/study/NCT02506959?tab=results"}]},"route":"/trials/nct02506959/","neighbours":{"cancer":[{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/"}],"drug":[{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/"},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/"}]}}